首页> 外文期刊>Mayo Clinic Proceedings >A Comparison of Long- and Short-Acting Opioids for the Treatment of Chronic Noncancer Pain: Tailoring Therapy to Meet Patient Needs
【24h】

A Comparison of Long- and Short-Acting Opioids for the Treatment of Chronic Noncancer Pain: Tailoring Therapy to Meet Patient Needs

机译:长效和短效阿片类药物治疗慢性非癌性疼痛的比较:量身定制的治疗方案,以满足患者的需求

获取原文
获取原文并翻译 | 示例
           

摘要

Management of chronic noncancer pain (CNCP) requires a comprehensive assessment of the patient, the institution of a structured treatment regimen, an ongoing reassessment of the painful condition and its response to therapy, and a continual appraisal of the patient's adherence to treatment. For many patients with CNCP, the analgesic regimen will include opioids. Physicians should consider the available evidence of efficacy, the routes of administration, and the pharmacokinetics and pharmacodynamics of the various formulations as they relate to the temporal characteristics of the patient's pain. When making initial decisions, physicians should decide whether to prescribe a short-acting opioid (SAO) with a relatively quick onset of action and short duration of analgesic activity, a long-acting opioid (LAO) with a longer duration of analgesic action but a potentially longer onset of action, or both. Studies suggest that SAOs and LAOs are both effective for most types of CNCP. A review of published studies found no data to suggest that either SAOs or LAOs are generally more efficacious for treating any particular CNCP condition. The LAOs may provide more stable analgesia with less frequent dosing; however, opioid therapy should be tailored to the pain state and the individual patient, and SAOs may be appropriate for some patients with CNCP. MEDLINE and PubMed searches were conducted to locate relevant studies published from January 1975 to April 2008 using the following search terms: opioids, short-acting opioids, long-acting opioids, chronic pain, chronic pain AND opioids, and narcotics. English-only randomized controlled trials and nonrandomized studies were considered.
机译:慢性非癌性疼痛(CNCP)的管理需要对患者进行全面评估,制定结构化的治疗方案,对疼痛状况及其对治疗的反应进行不断的重新评估,并持续评估患者对治疗的依从性。对于许多CNCP患者,镇痛方案将包括阿片类药物。医师应考虑与患者疼痛的时间特征相关的各种制剂的功效,给药途径以及药代动力学和药效动力学的可用证据。在做出初步决定时,医生应决定是否开具起效相对较快且镇痛作用持续时间较短的短效阿片类药物(SAO),而镇痛作用持续时间较长的长效阿片类药物(LAO)但可能开始更长的时间,或两者兼而有之。研究表明,SAO和LAO对大多数类型的CNCP均有效。对已发表研究的评论没有发现任何数据表明SAO或LAO通常可更有效地治疗任何特定的CNCP病状。 LAOs可以提供更稳定的镇痛效果,且给药频率较低;然而,阿片类药物的治疗应针对疼痛状态和患者的具体情况而定,SAO可能适合某些CNCP患者。进行了MEDLINE和PubMed搜索,以查找使用以下搜索词发表的1975年1月至2008年4月的相关研究:阿片类药物,短效阿片类药物,长效阿片类药物,慢性疼痛,慢性疼痛和阿片类药物以及麻醉药品。考虑了仅英语的随机对照试验和非随机研究。

著录项

  • 来源
    《Mayo Clinic Proceedings》 |2009年第7期|p.602-612|共11页
  • 作者单位

    CHARLES E. ARGOFF, MD, AND DANIEL I. SILVERSHEIN, MDFrom the Department of Neurology, Albany Medical College, Albany, NY (C.E.A.), and Department of Medicine, New York University Medical Center, New York, NY (D.I.S.).Dr Argoff acknowledges that he has served as a consultant/speaker for Endo Pharmaceuticals, King Pharmaceuticals, Pricara, Alpharma, and Cephalon and has served as a consultant for Abbott Laboratories. Dr Silvershein has acted as a consultant to the McMahon Group relating to their work with King Pharmaceuticals.Individual reprints of this article are not available. Address correspondence to Charles E. Argoff, MD, Department of Neurology, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208 (argoffc@mail.amc.edu).© 2009 Mayo Foundation for Medical Education and Research,;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号